Nexalin DIFS Neurostimulation Shows Cognitive Gains in Alzheimer’s Clinical Trials
Nexalin Technology Inc. has published three peer-reviewed studies on its DIFS™ technology for Alzheimer’s patients, showing cognitive improvements and enhanced brain activity without serious side effects. The findings suggest DIFS™ could serve as a non-invasive alternative to drug treatments. Further development and regulatory steps are planned based on these results.
Nexalin Technology Inc. has announced the publication of three independent, peer-reviewed clinical studies evaluating its Deep Intracranial Frequency Stimulation (DIFS™) technology for patients with Alzheimer’s disease and dementia. The results from these studies have already been presented in journals including “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology.” The studies collectively report that Nexalin’s non-invasive, drug-free DIFS™ device demonstrated improvements in cognitive function, brain activity, and neuronal connectivity in affected patients. The company highlights the absence of serious side effects and positions the device as a potential alternative to pharmaceutical treatments. Further development and regulatory advancement are planned based on these findings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549186-en) on October 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
